Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. Having examined the ...

Pharmaceutical company Eli Lilly announced promising clinical trial results this week for a daily pill to treat obesity and diabetes. Besides the good news of minimal side effects and impressive ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other Billionaire Ken Fisher’s healthcare stock picks with massive upside potential.

April 25 (Reuters) - Eli Lilly (LLY.N), opens new tab has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said on Friday. Last month ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

It promotes well-known treatments such as Mounjaro, Trulicity, Zepbound, Verzenio, and Jaypirca. Eli Lilly and Company (NYSE:LLY) surpassed expectations in 2024, exceeding initial sales guidance ...

Zepbound (tirzepatide) is a weekly injectable weight-loss medication. It can be purchased online or in person with a valid ...

Eli Lilly's Orforglipron shows promising Phase III results, potentially becoming a best-in-class oral GLP-1 receptor agonist for diabetes and obesity by 2026. Despite macroeconomic headwinds ...

A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the FDA’s crosshairs for the second time in less than a year.

The market expects Eli Lilly (LLY) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook ...

Pharmaceutical giant Eli Lilly and Co. sued Willow Health Services and three other companies in federal court in New Jersey and California, accusing them of selling unapproved compounded ...